Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | WNT3A | P56704 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733762 | 0.83 | FLT3 (0.59) | FLT3MAPK10ALDH1A1MAPTCTNNB1 | |
| SCHEMBL9778596 | 0.80 | MEN1 (0.64) | FLT3MAPK10ALDH1A1MAPTLMNA | |
| SCHEMBL21855639 | 0.76 | FLT3 (0.65) | FLT3MAPK10ALDH1A1MAPTLMNA | |
| SCHEMBL13779981 | 0.76 | FLT3 (0.69) | FLT3MAPK10ALDH1A1MAPTLMNA | |
| SCHEMBL3843612 | 0.75 | POLB (0.71) | ALDH1A1MAPTLMNA | |
| SCHEMBL6114106 | 0.75 | FLT3 (0.67) | FLT3MAPK10ALDH1A1MAPTLMNA | |
| SCHEMBL28477124 | 0.74 | ALDH1A1 (0.60) | FLT3ALDH1A1MAPTLMNA | |
| SCHEMBL1597230 | 0.74 | MAPK10 (0.83) | FLT3MAPK10MAPK8 | |
| SCHEMBL1597233 | 0.74 | MAPK10 (0.83) | FLT3MAPK10MAPK8 | |
| SCHEMBL1472881 | 0.74 | CTNNB1 (0.64) | FLT3ALDH1A1CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381366-B9 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1381366-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1381366-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6825201-B2 | ANTIVIRAL ACTIVITY; TREATMENT OF HIV AND AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1381366-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030096825-A1 | Indole, azaindole and related heterocyclic amidopiperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-05-22 | — | — | US | disclosed |
| WO-2002085301-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096825-A1 | Indole, azaindole and related heterocyclic amidopiperazine derivatives | IDO1, IDO2, INMT | FLT3 2902/4885MAPK10 4336/4885ALDH1A1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.